SCHEMBL19925792

SCHEMBL19925792

OCc1c[nH]c2nccc(Br)c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 2/20 0.43
GPR84 Q9NQS5 1/20 0.42
PRKCI P41743 2/20 0.41
MAPK1 P28482 1/20 0.39
PKM P14618 1/20 0.38
MET P08581 2/20 0.37
ITGB2 P05107 1/20 0.36
ICAM1 P05362 1/20 0.36
ITGAL P20701 1/20 0.36
MTNR1A P48039 1/20 0.35
JAK2 O60674 2/20 0.35
DAO P14920 1/20 0.35
LRRK2 Q5S007 5/20 0.35
HASPIN Q8TF76 1/20 0.35
ROCK2 O75116 2/20 0.35
ROCK1 Q13464 2/20 0.35
CDC42BPA Q5VT25 2/20 0.35
CDC7 O00311 1/20 0.35
PLK4 O00444 1/20 0.35
CHEK1 O14757 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30135074 0.83 PRKCI (0.41) AXLGPR84PRKCIMAPK1PKM
SCHEMBL28736869 0.81 KDM4E (0.43) AXLGPR84PRKCIMAPK1PKM
SCHEMBL3206828 0.79 CYP2D6 (0.54) AXLGPR84PRKCIMAPK1PKM
SCHEMBL1036038 0.77 MAPK1 (0.52) AXLPRKCIMAPK1PKMJAK2
SCHEMBL4596460 0.77 LRRK2 (0.42) AXLGPR84PRKCIPKMJAK2
SCHEMBL20422633 0.77 JAK2 (0.42) AXLPRKCIPKMITGB2ICAM1
SCHEMBL31541397 0.74 PRKCI (0.46) AXLPRKCIMAPK1PKMJAK2
SCHEMBL594143 0.74 PRKCI (0.46) AXLPRKCIMAPK1PKMJAK2
SCHEMBL4583627 0.73 PRKCI (0.44) AXLPRKCIMAPK1JAK2DAO
SCHEMBL19932612 0.73 CCNK (0.44) AXLPRKCIMAPK1DAOLRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11040026-B2 Muscarinic M1 receptor positive allosteric modulators SUVEN LIFE SCIENCES LIMITED (IN) 2021-06-22 US disclosed
US-11040026-B2 Muscarinic M1 receptor positive allosteric modulators SUVEN LIFE SCIENCES LIMITED (IN) 2021-06-22 US disclosed
EP-3507289-B1 MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS SUVEN LIFE SCIENCES LTD (IN) 2020-07-15 EP disclosed
EP-3507289-B1 MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS SUVEN LIFE SCIENCES LTD (IN) 2020-07-15 EP disclosed
US-20190343812-A1 MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS SUVEN LIFE SCIENCES LIMITED (IN) 2019-11-14 US disclosed
US-20190343812-A1 MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS SUVEN LIFE SCIENCES LIMITED (IN) 2019-11-14 US disclosed
EP-3507289-A1 MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS Suven Life Sciences Limited (IN) 2019-07-10 EP disclosed
WO-2018042362-A1 MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS SUVEN LIFE SCIENCES LIMITED (IN) 2018-03-08 WO disclosed
WO-2018042362-A1 MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS SUVEN LIFE SCIENCES LIMITED (IN) 2018-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11040026-B2 Muscarinic M1 receptor positive allosteric modulators CHRM1, CHRM2, CHRM3 AXL 1261/4885GPR84 68/4885PRKCI 2046/4885
US-20190343812-A1 MUSCARINIC M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS CHRM1, CHRM2, CHRM3 AXL 1261/4885GPR84 68/4885PRKCI 2046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.